This is the authors' abstract. We don't add key points for this paper.
Breast cancer, a prevalent type of cancer, poses a significant threat to women’s health. The emergence of chemotherapy resistance is a major challenge in the clinical treatment of breast cancer. In this study, we constructed a nanodrug-carrying system (miR-200c/DOX@Ti 3 C 2 /HA-ADH, abbreviated as DTH-200c), a two-dimensional MXene-based platform for the co-delivery of miR-200c and doxorubicin (DOX). This system employs hyaluronic acid-adipic dihydrazide (HA-ADH) to enhance tumor targeting and the nanomaterial’s stability. EMT (epithelial-mesenchymal transition) induced by the TGF-[Formula: see text]/Smad pathway is one of the main reasons for the emergence of drug resistance in tumors, and it has been demonstrated that miR-200c can affect the occurrence of EMT, thereby alleviating drug resistance. In vitro studies demonstrate that DTH-200c significantly reduces the IC 50 of DOX fivefold, effectively reversing EMT-mediated drug resistance and suppressing the proliferation and migration of breast cancer cells. This nanosystem presents a novel therapeutic avenue for alleviating drug resistance in drug-resistant breast cancers.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Wen et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: